ReviewMolecules (Basel, Switzerland)2025
Excipients for Cerium Dioxide Nanoparticle Stabilization in the Perspective of Biomedical Applications.
Review in Molecules (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Stabilization of Nanodispersed Cerium Phosphate in Matrices Containing Cellulose Derivatives, Citric Acid and Metronidazole.Polymers · 2026Article
- Novel Cerium Phosphate-Citric Acid Nanocomposites for Biomedical Applications in Regenerative Medicine: In Vitro and In Vivo Study.International journal of molecular sciences · 2026Article
- Nanosized Cerium Phosphate: Synthesis Methods, Morphology, and Potential Applications in Biomedicine.Biomedicines · 2026Review
- Biological Applications of Functionalized Cerium Oxide Nanoparticles.International journal of medical sciences · 2026Review
- The Effectiveness of Cerium Oxide Nanoparticle-Based Drugs in Wound Healing in Animal Models.Molecules (Basel, Switzerland) · 2025Review
- Development of a Collagen-Cerium Oxide Nanohydrogel for Wound Healing: In Vitro and In Vivo Evaluation.Biomedicines · 2025Article
- Cerium Phosphate Nanoparticles: Synthesis, Characterization, Biocompatibility, Regenerative Potential, and Antioxidant Activity.Molecules (Basel, Switzerland) · 2025Article
- Phase-Inversion In Situ Systems: Problems and Prospects of Biomedical Application.Pharmaceutics · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Rare earth metal nanoparticles, some of which are already widely used in medicine, are of growing interest in the modern scientific community. One of the promising rare earth metals for biomedical applications is cerium, specifically its oxide form, which is characterized by a higher level of stability and safety. According to a number of studies, cerium dioxide has a wide range of biological effects (regenerative, antimicrobial, antioxidant, antitumor), which justifies the interest of its potential application in medicine. However, these effects and their intensity vary significantly across a number of studies. Since cerium dioxide was used in these studies, it can be assumed that not only is the chemical formula important, but also the physicochemical parameters of the nanoparticles obtained, and consequently the methods of their synthesis and modification with the use of excipients. In this review, we considered the possibilities of using a number of excipients (polyacrylate, polyvinylpyrrolidone, dextran, hyaluronic acid, chitosan, polycarboxylic acids, lecithin, phosphatidylcholine) in the context of preserving the biological effects of cerium dioxide and its physicochemical properties, as well as the degree of study of these combinations from the point of view of the prospect of creating drugs based on it for biomedical applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.